Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can a bedside clotting test predict which brain tumor patients face deadly blood clots?

NCT ID NCT07813377

Diagnosis Sponsor: Fundacion Clinic per a la Recerca Biomédica Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Sep 10, 2026 · Last updated Sep 11, 2026 · Updated 1 time

Summary

Researchers are studying whether thromboelastography, a blood test that measures clot formation, can predict outcomes for people having surgery for glial brain tumors. The trial enrolls about 100 adults who are scheduled for tumor removal or biopsy. By tracking clotting measurements alongside molecular tumor markers and postoperative thrombotic events, the team aims to learn whether this test can help reduce dangerous blood clots and guide cancer treatment.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
thromboelastography, a blood test that measures how quickly and firmly clots form
What this could lead to
If the test proves useful, doctors could flag which brain tumor patients face the highest risk of dangerous blood clots after surgery and adjust monitoring or prevention accordingly.
What could go wrong
This is an observational study of 100 people at one set of hospitals, so it can only show associations, not prove that the test changes outcomes. The findings may not hold in other patient groups or centers.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 100 people

The number the study aims to enrol. It can still change while the study runs.

Started

May 2026

Expected to finish

May 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Patients undergoing surgical excision or biopsy with a diagnostic impression of glial tumor who provide written informed consent

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Patients undergoing surgical excision or biopsy with a diagnostic impression of glial tumor who provide written informed consent Exclusion Criteria: * Patients under 18 years of age. * Emergency surgery. * Patients receiving antiplatelet or anticoagulant treatment. * Patients with known hematologic diseases associated with coagulation abnormalities. Examples include: * Congenital or acquired platelet function disorders. * Congenital deficiency of protein C or protein S. * Deficiency of coagulation factors II, V, VII, X, XII. * Glanzmann thrombasthenia. * Hemophilia A, B, or C. * Idiopathic thrombocytopenic purpura (ITP). * von Willebrand disease (types I, II, and III). * Systemic diseases that cause significant coagulation time alterations: * Prothrombin time \< 60%. * Activated partial thromboplastin time (aPTT) \> 50 seconds. * Patients with suspected glial or neuroglial tumor in the context of long-standing epilepsy

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Glial tumors are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

disease glioma pulmonary embolism thrombotic disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Glial tumors Pulmonary embolism (diagnosis) Thrombosis

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Hospital Clínic Barcelona

    RECRUITING

    Barcelona, 08036, Spain

More trials for these conditions

Other studies related to the condition(s) this trial covers.